Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples